The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells.

The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells.

CLL cell trafficking between blood and tissue compartments is an integral part of the disease process. Idelalisib, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor causes rapid lymph node shrinkage, along with an increase in lymphocytosis, prior to inducing objective responses in CLL patients. Th...

Full description

Bibliographic Details
Main Authors: Stefania Fiorcari, Wells S Brown, Bradley W McIntyre, Zeev Estrov, Rossana Maffei, Susan O'Brien, Mariela Sivina, Julia Hoellenriegel, William G Wierda, Michael J Keating, Wei Ding, Neil E Kay, Brian J Lannutti, Roberto Marasca, Jan A Burger
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3871531?pdf=render

Internet

http://europepmc.org/articles/PMC3871531?pdf=render

Similar Items